STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries

The GLOBE pilot isn’t expected to have much impact, but it would set a precedent the biotech industry wants to nip in the bud Adobe Nov. 7, 2026 John Wilkerson, a Washington correspondent, is the author of D.C. Diagnosis, a twice-weekly newsletter about the politics and policy of health and medicine. John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. WASHINGTON — The Biotechnology Innovation Organization is joining the legal fight against the Trump administration’s pilot program aimed at aligning drug prices in Medicare with prices charged in peer countries. BIO and two California-based biotech trade groups filed a complaint Friday in the U.S. District Court for the Northern District of California asserting that the Global Benchmark for Efficient Drug Pricing demonstration, known as GLOBE, oversteps Medicare’s statutory authority. The complaint seeks to halt the model. The Centers for Medicare and Medicaid Services did not immediately respond to a request for comment. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.